Strategic hiring Centese recently added Timothy Still to its Board of Directors, signaling a push to strengthen leadership for its next growth phase. Sales opportunities may arise from an expanded governance focus and potential partnerships with institutions aligned with new strategic directions.

Clinical validation Multiple peer‑reviewed studies and clinical analyses have been conducted and published around Thoraguard for cardiac and thoracic surgery, including Stanford University Medical Center involvement. This provides a strong clinical value proposition and a solid case for hospital procurement conversations.

Digitalization trend Thoraguard emphasizes intelligent, digital drainage management that replaces archaic manual processes. Hospitals investing in digital patient management and automated monitoring are likely customers, particularly in cardiothoracic and pulmonary departments.

Growth readiness With reported revenue between one and ten million and a significant funding cushion, Centese appears equipped to scale. Potential opportunities include pilot programs, expanded deployments, or partnerships with larger medical device distributors seeking innovative drainage solutions.

Market credibility A history of clinical studies and press coverage dating back to 2020 demonstrates ongoing product validation and visibility in medical journals and newsrooms. This can facilitate introductions to key decision makers at tertiary care centers and academic hospitals.